Drug Profile
JI 101
Alternative Names: CGI-1842; JI-101Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CGI Pharmaceuticals
- Developer Jubilant Innovation; University of Utah
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; EphB4 inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Jan 2012 Jubilant Innovation completes a phase I/II trial in Solid tumours in US (NCT00842335)
- 16 Nov 2010 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2010)
- 19 Nov 2009 Interim adverse events data from a phase I trial and pharmacodynamic data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)